INDP Indaptus Therapeutics, Inc.

Indaptus Therapeutics Inc is positioned to revolutionize the treatment of cancer and certain infectious diseases. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. Its pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.

$1.90  +0.09 (4.97%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  08/04/2015
Outstanding shares:  8,401,047
Average volume:  9,348
Market cap:   $15,205,895
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%